Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction

被引:59
|
作者
Wang, Shuai [1 ,2 ,6 ,7 ]
Zhao, Lijie [1 ,2 ,6 ,7 ]
Shi, Xiao-Jing [1 ,2 ,6 ,7 ]
Ding, Lina [1 ,2 ,6 ,7 ]
Yang, Linlin [8 ]
Wang, Zhi-Zheng [1 ,2 ,6 ,7 ]
Shen, Dandan [1 ,2 ,6 ,7 ]
Tang, Kai [1 ,2 ,6 ,7 ]
Li, Xiao-Jing [1 ,2 ,6 ,7 ]
Mamun, M. A. A. [1 ,2 ,6 ,7 ]
Li, Huiju [1 ,2 ,6 ,7 ]
Yu, Bin [1 ,2 ,6 ,7 ,9 ]
Zheng, Yi-Chao [1 ,2 ,6 ,7 ]
Wang, Shaomeng [1 ,2 ,3 ,4 ,5 ]
Liu, Hong-Min [1 ,2 ,6 ,7 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Inst Drug Discovery & Dev, Zhengzhou 450001, Henan, Peoples R China
[3] Univ Michigan, Dept Internal Med, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pharmacol, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Med Chem, 1600 Huron Pkwy, Ann Arbor, MI 48109 USA
[6] Coinnovat Ctr Henan Prov New Drug R&D Preclin Saf, Zhengzhou 450001, Henan, Peoples R China
[7] Zhengzhou Univ, Minist Educ China, Key Lab Adv Technol Drug Preparat Technol, Zhengzhou 450001, Henan, Peoples R China
[8] Zhengzhou Univ, Sch Basic Med Sci, Dept Pharmacol, Zhengzhou 450001, Henan, Peoples R China
[9] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划; 中国博士后科学基金;
关键词
CULLIN-RING LIGASES; NEDD8-ACTIVATING ENZYME; E3; LIGASE; DEGRADATION; NEDDYLATION; DISCOVERY; CARCINOMA; UBIQUITINATION; AMPLIFICATION; PROGRESSION;
D O I
10.1021/acs.jmedchem.9b00113
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.
引用
收藏
页码:2772 / 2797
页数:26
相关论文
共 39 条
  • [1] Targeting the DCN1-UBC12 Protein-protein Interaction for Selective Modulation of Cullin Substrates
    Fang, Yuan
    Yu, Lei
    Liao, Guochao
    Yu, Bin
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (17) : 1423 - 1425
  • [2] Structure-based design of highly potent small-molecule inhibitors of DCN1-UBC12 protein-protein interaction
    Zhou, Haibin
    Lu, Jianfeng
    Liu, Liu
    Bernard, Denzil
    Stuckey, Jeanne
    Sun, Yi
    Wang, Shaomeng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [3] Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway
    Zhou, Haibin
    Lu, Jianfeng
    Yang, Chao-Yie
    Sun, Yi
    Wang, Shaomeng
    CULLIN-RING LIGASES AND PROTEIN NEDDYLATION: BIOLOGY AND THERAPEUTICS, 2020, 1217 : 349 - 362
  • [4] Targeting the DCN1-UBC12 protein-protein interaction: novel approaches and future directions
    Fang, Yuan
    Yu, Bin
    Liao, Guochao
    Liu, Hong-Min
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (22) : 2869 - 2871
  • [5] Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects
    He, Zhang-Xu
    An, Qi
    Wei, Bo
    Zhou, Wen-Juan
    Wei, Bing-Fei
    Gong, Yun-Peng
    Zhang, Xin
    Gao, Ge
    Dong, Guan-Jun
    Huo, Jin-Ling
    Zhang, Xin-Hui
    Yang, Fei-Fei
    Liu, Hong-Min
    Ma, Li-Ying
    Zhao, Wen
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (01) : 163 - 190
  • [6] Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction
    Zhou, Wenjuan
    Xu, Chenhao
    Dong, Guanjun
    Qiao, Hui
    Yang, Jing
    Liu, Hongmin
    Ding, Lina
    Sun, Kai
    Zhao, Wen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 217
  • [7] High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein Protein Interaction
    Zhou, Haibin
    Zhou, Weihua
    Zhou, Bing
    Liu, Liu
    Chern, Ting-Rong
    Chinnaswamy, Krishnapriya
    Lu, Jianfeng
    Bernard, Denzil
    Yang, Chao-Yie
    Li, Shasha
    Wang, Mi
    Stuckey, Jeanne
    Sun, Yi
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (05) : 1934 - 1950
  • [8] Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors
    Shen, Jian
    Deng, Xinxian
    Sun, Ran
    Tavallaie, Mojdeh S.
    Wang, Juntao
    Cai, Qingqing
    Lam, Celine
    Lei, Shuwen
    Fu, Lei
    Jiang, Faqin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208
  • [9] Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer
    Li, Anqi
    Ma, Ting
    Wang, Shuai
    Guo, Yueyang
    Song, Qianqian
    Liu, Hongmin
    Yu, Bin
    Feng, Siqi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [10] Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators
    Wang, Shuai
    Wang, Sai-Qi
    Teng, Qiu-Xu
    Yang, Linlin
    Lei, Zi-Ning
    Yuan, Xiao-Han
    Huo, Jun-Feng
    Chen, Xiao-Bing
    Wang, Mengru
    Yu, Bin
    Chen, Zhe-Sheng
    Liu, Hong-Min
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (24) : 15979 - 15996